I want to thank you for the work that you have done--when the Super Committee was supposed to be doing its work, and not doing its work terribly well.
I am encouraging this Congress to basically say we have had enough of this divisive discussion; let us solve this problem.
We have, as you know, an enormous sense of urgency about it because there are the safety issues that you mentioned;
I think there are ways that we could think more creatively that fund something a little bit like the Home Owner Loan Corporation.
I think the Administration bringing this up is important.
I do not get it when you could create a large base of continuing responsible borrowers at the end of the day.
Actually, while we're on that topic, just out of curiosity, what do we know about drug shortages in other countries?
Their urgency caused me to send a letter to FDA Commissioner Hamburg urging the FDA to take actions to address this public health crisis.
The FDA has been notified about 220 drug shortages this year, and we know that the number of patients this affects is monumental.
Thank you very much, both of you, for your work on all of this. And, Mr. Chairman, thank you for holding this hearing.
Are there differences in the categories of drugs that are in short supply in other places?